Summit Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Summit Therapeutics Inc 's ROA in the third quarter of 2026?
Summit Therapeutics Inc recorded a cumulative net loss of $-833 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -117.15%.

However, within the Healthcare sector 806 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4565, from total ROA ranking in the second quarter of 2026 at 5283.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	164.97 %	132.26 %	68.85 %	452.11 %	130.15 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-833	-856	-1,206	-1,080	-922
Return On Assets (TTM)	-117.15 %	-141.97 %	-243.18 %	-251.09 %	-333.71 %
SMMT's Total Ranking	# 4565	# 5283	# 4698	# 4689	# 4270
Total Assets (TTM) in million	693	752	648	751	261
Seq. Total Assets Change	-7.88 %	16.11 %	-13.8 %	187.36 %	-19.25 %
Seq. Net Income Change	-	-	-	-	-

SMMT's 5 Years Annual ROA >> Back to SMMT Management Effectiveness >> Compare SMMT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 380
Sector	# 807
Overall	# 4371

Return On Assets Statistics
High	Average	Low
13.96 %	-89.2 %	-269.21 %
(Dec 31 2019)		(Dec 31 2023)

Financial Statements
Summit Therapeutics Inc 's Assets	$ 693 million	SMMT's Balance sheet
Summit Therapeutics Inc 's Income	$ -208 million	Quarterly SMMT's Income Statement
SMMT's Income by Division		See SMMT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	38.07 %	-21.86 %	-76.7 %	320.6 %	24.21 %
Total Assets in million	188	136	174	747	178
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-1,080	-221	-615	-79	-89
Annual Return On Assets	-574.71 %	-162.66 %	-353.18 %	-10.54 %	-49.87 %

SMMT's 5 Years Annual ROA >> Back to SMMT Management Effectiveness >> Compare SMMT ROA to its Competitors

More Return On Assets Ratios
SMMT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SMMT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SMMT's Competitors
Subscribers only: Roa for Summit Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for SMMT's Customers

You may also want to know
SMMT's Roi	SMMT's Inventory Turnover Ratio	SMMT's Growth Rates	SMMT's Dividend Comparisons
	SMMT's Profitability Ratios	SMMT's Asset Turnover Ratio	SMMT's Dividend Growth
SMMT's Roe	SMMT's Valuation Ratios	SMMT's Financial Strength Ratios	SMMT's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-05T06:40:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.